SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced the completion of patient enrollment in the U.S. Investigational New Drug (IND) Phase II study of its Travoprost Intraocular Implant with the iDose™ delivery system in patients with glaucoma. Implanted during a micro-invasive proce
Category: Business
NightstaRx Appoints Ophthalmology Industry Veteran Scott Whitcup to Board of Directors
BOSTON–(BUSINESS WIRE)–NightstaRx Appoints Ophthalmology Industry Veteran Scott Whitcup to Board of Directors
AptarGroup Reports Increased First Quarter Revenue and Earnings; Continued Investment in Connected Electronic Drug Delivery Devices
CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE:ATR) today announced increased revenue, net income and earnings per share for the first quarter of 2017. In addition, AptarGroup announced its continued investment in the field of connected el…
Global Wet Age Related Macular Degeneration (AMD) Market Analysis & Outlook 2017-2021 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Wet Age Related Macular Degeneration (AMD) Market: Industry Analysis & Outlook (2017-2021)” report to their offering. “Global Wet AMD Market: Industry Analysis & Outlook (2017-2021)” analyses the development of this market, with focus on the U.S. and outside the U.S. markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four
Optovue est la première entreprise à lancer sur le marché l’angiographie OCT haute densité en ophtalmologie
FREMONT, Californie–(BUSINESS WIRE)–Optovue, le leader mondial dans le développement de la tomographie par cohérence optique (OCT, Optical Coherence Tomography) et de l’angiographie OCT (OCTA, OCT Angiography ), est la première entreprise à proposer des images OCTA de densité supérieure qui apportent des améliorations significatives dans la résolution et la visualisation périphérique de la circulation vasculaire de l’œil. L’imagerie AngioVueHD, qui est distribuée commercialement par Optovue a
Optovue veröffentlicht als erster Anbieter eine OCT-Angiografie mit hoher Dichte für die Augenheilkunde (Ophthalmologie)
FREMONT, Kalifornien (USA)–(BUSINESS WIRE)–Optovue, der weltweit führende Entwickler von optischer Kohärenztomografie (OCT) und OCT-Angiografie (OCTA), ist das erste Unternehmen, das OCTA-Bildgebung mit höherer Dichte anbietet. Sie sorgt für eine maßgebliche Verbesserung der Auflösung und peripheren Visualisierung der Gefäßanordnung im Auge. Die AngioVueHD-Bildgebung, die heute von Optovue in den Handel gegeben wurde, liefert OCTA-Scans mit 73 Prozent mehr Abtastpunkten* und verbessert die Bi
RightEye Launches Revolutionary Eye-Tracking Test to Identify Reading Disorders in Students at All Grade Levels
WASHINGTON–(BUSINESS WIRE)–#COVD–RightEye, a technology innovator using eye tracking to revolutionize patient care and vision performance, launches revolutionary reading test to identify reading disorders in students of all ages.
Ophthotech Corporation to Report First Quarter 2017 Financial Results and Host Conference Call on Wednesday, May 3, 2017
NEW YORK–(BUSINESS WIRE)–Ophthotech today announced that it will report its first quarter 2017 financial and operating results on Weds., May 3. Following the announcement, Ophthotech will host a live conference and webcast.
Riassunto: Optovue lancia per prima l’angiografia OCT per applicazioni oftalmologiche
FREMONT, California–(BUSINESS WIRE)–Optovue, leader globale nello sviluppo della tomografia a coerenza ottica (optical coherence tomography, OCT) e dell’angiografia OCT (OCT angiography, OCTA), è la prima azienda a offrire l’imaging OCTA ad alta densità, che consente un miglioramento significativo in termini di risoluzione e visualizzazione della vascolarizzazione periferica dell’occhio. L’imaging AngioVueHD, lanciata oggi sul mercato da Optovue, offre scansioni OCTA con il 73% di punti di ca
Optovue First to Release High Density OCT Angiography for Ophthalmology
FREMONT, Calif.–(BUSINESS WIRE)–Optovue, the global leader in the development of optical coherence tomography (OCT) and OCT angiography (OCTA), is the first company to offer higher density OCTA imaging that provides significant improvement in resolut…
United States Market Report for Corneal Topographers 2017 – Unit Sales, ASPs, Market Value & Growth Trends – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “US Market Report for Corneal Topographers 2017 – MedCore” report to their offering. This market includes Placido ring and Schiempflug camera topographers. The total market…
Optovue First to Release High Density OCT Angiography for Ophthalmology
FREMONT, Calif.–(BUSINESS WIRE)–Optovue is the first company to offer higher density OCTA imaging that provides a significant improvement in resolution and peripheral visualization in the vasculature in the eye.
Medsphere Solves Client, VA Scheduling Challenges with New Solutions
CARLSBAD, Calif.–(BUSINESS WIRE)–Medsphere today introduced a new Scheduler tool for the company’s electronic health records (EHRs).
Mati Therapeutics Hits Major Milestone with 100 Patents
AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics announced that its international patent portfolio now comprises 100 issued patents. The patents include elements of the Evolute® punctal plug for treatment of ocular indications.
Second Sight to Discuss First Quarter 2017 Financial Results on May 3, 2017 Conference Call
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to provide some useful vision to blind patients, will release its first quart…
Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Intravitreal Sirolimus (DE-109) in the Treatment of Non-Infectious Uveitis of the Posterior Segment
OSAKA, Japan–(BUSINESS WIRE)–The U.S. FDA has accepted Santen’s NDA for intravitreal (IVT) sirolimus (440 µg) for the treatment of non-infectious uveitis of the posterior segment. The PDUFA action date is December 24, 2017.
Aerie Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 2, 2017
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), (the “Company”), announced today that its first quarter 2017 financial results will be released after the market closes on Tuesday, May 2, 2017. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company’s website at http://
US Market Report for Perimeters 2017: Sales are Relatively Immune to Economic Crises – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “US Market Report for Perimeters 2017 – MedCore” report to their offering. The slow but steady growth of the perimeter market is stimulated by the aging population and thei…
US Market Report for Autorefractors and Keratometers 2017: Driven by Increasing Popularity of Three-in-One Combination Devices – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “US Market Report for Autorefractors and Keratometers 2017 – MedCore” report to their offering. There were essentially no standalone autorefractor or keratometer devices le…
US Market Report for Optical Biometry 2017: Driven by Expansion of New & Existing Cataract Surgery Practices – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “US Market Report for Optical Biometry 2017 – MedCore” report to their offering. The optical biometry device market is expected to grow over the forecast period due to sust…